Publications & Presentations
Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development
London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening
Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development Read More »
Pulmocide announces four presentations on PC945 at the 9th Advances Against Aspergillosis and Mucormycosis conference in Lugano, Switzerland, 27 February – 1 March, 2020
London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung